In June 2021, the Food and Drug Administration (FDA) finalized guidance for industry (GFI) #263, a directive that recommends sponsors of “medically important” antimicrobial drugs that are currently approved with over the counter (OTC) marketing status voluntarily switch to Rx status. To better prepare the animal and food production industries for the shift, Arm & Hammer has released a series of #ScienceHearted resources.
While guidance #263 isn’t slated for final implementation until June 11, 2023, many products…
